Thursday 17th of March 2022 10:58:59 AM
AstraZeneca ready to drop plans for U.S. regulatory approval of COVID-19 shot - FT
Roland Magnusson/iStock Editorial via Getty Images
AZN PFE BNTX MRNA JNJ
- A senior executive at the Anglo-Dutch vaccine maker, AstraZeneca (NASDAQ:AZN), said Thursday that the company would consider not submitting its COVID-19 shot for approval in the U.S. if the regulatory process takes too long, The Financial Times reported.
- “We don’t need to push it in places we are not needed or wanted,” Sir Mene Pangalos, AstraZeneca’s (AZN) head of research and development, told the paper on Thursday.
- Instead, the company will focus on selling the vaccine in other countries though it will continue the talks with the U.S. Food and Drug Administration (FDA), Pangalos added.
- “If we don’t end up submitting it for a BLA [biologics licence application], I don’t think it will have an impact around the world,” he added.
- So far, the FDA has authorized only three COVID-19 vaccines. In late 2020, it greenlighted messenger RNA-based vaccines from Pfizer (PFE)/ BioNTech (BNTX) and Moderna (MRNA), and in early 2021, the regulator cleared the single-dose vector-based shot from Johnson & Johnson (JNJ).